Charles Schwab Investment Management Inc. Acquires 12,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Charles Schwab Investment Management Inc. lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 623,749 shares of the biotechnology company’s stock after purchasing an additional 12,000 shares during the period. Charles Schwab Investment Management Inc. owned about 0.65% of Sarepta Therapeutics worth $75,842,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in SRPT. QRG Capital Management Inc. bought a new position in shares of Sarepta Therapeutics in the third quarter worth approximately $246,000. Assetmark Inc. grew its holdings in shares of Sarepta Therapeutics by 230.6% in the third quarter. Assetmark Inc. now owns 39,025 shares of the biotechnology company’s stock worth $4,874,000 after purchasing an additional 27,220 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of Sarepta Therapeutics by 16.1% in the third quarter. Crossmark Global Holdings Inc. now owns 7,161 shares of the biotechnology company’s stock worth $894,000 after purchasing an additional 994 shares during the last quarter. WCM Investment Management LLC grew its holdings in shares of Sarepta Therapeutics by 32.5% in the third quarter. WCM Investment Management LLC now owns 10,917 shares of the biotechnology company’s stock worth $1,359,000 after purchasing an additional 2,680 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Sarepta Therapeutics by 21.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,700 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 300 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is currently owned by company insiders.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $99.69 on Tuesday. The stock has a market cap of $9.67 billion, a price-to-earnings ratio of 79.75 and a beta of 0.79. The firm’s 50-day moving average is $113.68 and its 200 day moving average is $120.98. Sarepta Therapeutics, Inc. has a 1 year low of $98.82 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Analyst Ratings Changes

SRPT has been the topic of several recent analyst reports. HC Wainwright restated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Piper Sandler dropped their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft assumed coverage on Sarepta Therapeutics in a research note on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target for the company. Scotiabank assumed coverage on Sarepta Therapeutics in a research note on Friday. They issued a “sector perform” rating and a $105.00 price target for the company. Finally, Royal Bank of Canada dropped their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $170.41.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.